Plain-English translation of NCT02026843 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying biological markers—measurable signs in eye fluid and blood—that may help them better understand and treat serious eye diseases like diabetic retinopathy and age-related macular degeneration. This is a comparison study where some participants have these eye diseases and others do not, so scientists can identify what's different and what matters for treatment.
Many eye diseases cause vision loss, but doctors don't fully understand all the underlying causes or how to predict which patients will improve with treatment. By analyzing the biological markers in eye fluid and blood, researchers hope to discover better ways to diagnose and treat these conditions in the future.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would visit the hospital before your already-scheduled eye procedure. During this visit, doctors will collect a small sample of fluid from your eye and a blood sample, which will be analyzed for biological markers. The sampling takes place on the day of or just before your surgical procedure, so there are no extra visits beyond what you're already having for your treatment.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
South Korea
Sponsor
Kyungpook National University Hospital
Enrollment target
~100 participants
Started
April 2012
Primary completion
February 2028
Age range
20 Years – 80 Years
Last updated on clinicaltrials.gov in March 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Dong Ho Park, M.D.
Kyungpook National University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.